Grifols (GRFS) Financial Analysis & Valuation | Quarter Chart
Grifols (GRFS)
GRFSPrice: $7.33
Fair Value: 🔒
🔒score
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plas... more
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products... more
Description
Shares
| Market Cap | $6.20B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | ES | CEO | Jose Ignacio Abia Buenache |
| IPO Date | 2011-06-02 | CAGR | 0.14% |
| Employees | 23,833 | Website | www.grifols.com |
| Div. Yield | 1.8% | Payout Ratio | 0.31% |
| Buy Back Yield | 2.16% | Total Yield | 3.96% |
GRFS chart loading...
Fundamentals
Technicals
| Enterprise Value | $13.16B | P/E Ratio | 8.42 |
| Forward P/E | 5.07 | PEG Ratio | — |
| P/S Ratio | 0.75 | P/B Ratio | 1.02 |
| P/CF Ratio | 5.51 | P/FCF Ratio | 7.48 |
| EPS | $0.87 | EPS Growth 1Y | 114.86% |
| EPS Growth 3Y | 191.17% | EPS Growth 5Y | -26.33% |
| Revenue Growth 1Y | 1.02% | Gross Margin | 0.38% |
| Operating Margin | 0.17% | Profit Margin | 0.06% |
| ROE | 0.08% | ROA | 0.02% |
| ROCE | 0.07% | Current Ratio | 2.47 |
| Quick Ratio | 0.85 | Cash Ratio | 0.33 |
| Debt/Equity | 1.77 | Interest Coverage | 2.04 |
| Altman Z Score | 1.01 | Piotroski Score | 6 |